THE LABORATORY OF PATHOPHYSIOLOGY AND THERAPIES FOR VISION DISEASES, PART OF THE JOINT RESEARCH UNIT ON RARE DISEASES CIPF-IIS La Fe and a member of CIBERER, focuses on the development of neuroprotective pharmacological therapies for degenerative retinal diseases such as retinitis pigmentosa and diabetic retinopathy.

It employs cellular and animal models to study the mechanisms of neurodegeneration and to advance therapeutic strategies with clinical potential. The lab has translated part of its research into patient-oriented studies, including NUTRARET and the ADARET clinical trial.

Its research lines include anti-inflammatory therapies, antioxidants, and bioactive lipids derived from omega-3. In recent years, the lab has incorporated the use of both polymeric and lipid-based nanocarriers, in collaboration with specialized groups in nanotechnology.

It is equipped with tools to assess visual function in vivo, such as electroretinography (ERG), fundus imaging, and behavioral tests. The group actively collaborates with hospitals such as La Fe, Clínico, and Manises, as well as with patient associations, particularly RETINA CV, to ensure clinical translation of its findings. In addition, the lab maintains a strong commitment to scientific outreach and public engagement. Its projects are funded by the Instituto de Salud Carlos III (ISCIII), Fundación ONCE, Generalitat Valenciana, among others.

PRESENTATION

GET TO KNOW US BETTER

  • Own scientific image of the laboratory
  • Own scientific image of the laboratory

RESEARCH STAFF

THE PEOPLE WHO MAKE IT ALL POSSIBLE

Regina Rodrigo Nicolás
rrodrigo@cipf.es

M Carmen Castro Quero
mcastro@cipf.es

Isabel Campillo Nuevo
icampillo@cipf.es

PUBLICATIONS

OUR SCIENTIFIC CONTRIBUTIONS

Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy.

Velasco S, Gallego I, Olivares-González L, Puras G, Castro MC, Salom D, Pedraz JL and Rodrigo R

BIOMEDICINE & PHARMACOTHERAPY 2025 Apr,  DOI:  10.1016/j.biopha.2025.117962,  Vol. 185,  pag. 117962-117962

READ PUBLICATION

An SPM-Enriched Marine Oil Supplement Shifted Microglia Polarization toward M2, Ameliorating Retinal Degeneration in rd10 Mice.

Olivares-González L, Velasco S, Gallego I, Esteban-Medina M, Puras G, Loucera C, Martínez-Romero A, Peña-Chilet M, Pedraz JL and Rodrigo R

Antioxidants 2022 Dec,  DOI:  10.3390/antiox12010098,  Vol. 12,  pag. 

READ PUBLICATION

NUTRARET: Effect of 2-Year Nutraceutical Supplementation on Redox Status and Visual Function of Patients With Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Trial

L. OLIVARES-GONZALEZ, D. SALOM, E. GONZALEZ-GARCIA, D. HERVAS, N. MEJIA-CHIQUI, M. MELERO, S. VELASCO, B. MURESAN, I. CAMPILLO, N. VILA-CLERIGUES, E. LOPEZ-BRIZ, J. MERINO-TORRES, J. MILLAN, J. DEL CASTILLO and R. RODRIGO

Frontiers in Nutrition 2022 Mar,  DOI:  10.3389/fnut.2022.847910,  Vol. 9,  pag. 847910-847910

READ PUBLICATION

The mechanistic functional landscape of retinitis pigmentosa: a machine learning-driven approach to therapeutic target discovery

M. ESTEBAN-MEDINA, C. LOUCERA, K. RIAN, S. VELASCO, L. OLIVARES-GONZÁLEZ, R. RODRIGO, J. DOPAZO and M. PEÑA-CHILET

Journal of Translational Medicine 2024 Feb,  DOI:  10.1186/s12967-024-04911-7,  Vol. 22,  pag. 139-139

READ PUBLICATION

Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice.

Olivares-González L, Velasco S, Millán JM and Rodrigo R

FASEB JOURNAL 2020 Oct,  DOI:  10.1096/fj.202000044RR,  Vol. 34,  pag. 13839-13861

READ PUBLICATION

FUNDING

THANK YOU FOR SUPPORTING US